Clinical Trials · NCT04919226
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- ITM Solucin GmbH
- Enrollment
- 259
- Start date
- Dec 2021
- Locations
- 42 sites, 10 countries
- Primary endpoint
- Progression-Free Survival